A-106 Concentrating Antibodies at Mucosal Frontlines for Prevention. (March 2017)

• Record Type: Journal Article
• Authors: Haase, Ashley
• Is Part Of: Journal of acquired immune deficiency syndromes. Volume 74(2017)Supplement 3
• Publication Date: 2017-03
• Subjects: AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome -- Periodicals; AIDS (Disease); Periodicals; 616.9792005
• DOI: 10.1097/01.qai.0000513816.80841.63
• Languages: English
• ISSNs: 1525-4135

Abstract

Abstract : Understanding the robust protection conferred by the live attenuated SIV vaccine, SIV-delta nef, could provide guiding principles for development of an effective HIV vaccine. In studies in the SIV-rhesus macaque model of HIV transmission to women, SIV-delta nef vaccination has been shown to elicit non-neutralizing antibodies that react with trimeric gp41 (gp41 t) and are concentrated by the neonatal Fc receptor (FcRn) in cervical-vaginal epithelium on the path of virus entry, as one potential correlate of protection. I will review the pathogenesis studies that revealed this potential correlate and describe the current status of reproducing SIV-delta nef protection with gp41 t immunogens, adjuvants and an immunization protocol that mimics the persistent antigen exposure of infection.